Under the deal, Peptris Technologies is licensing PEPR124 (RT001), a preclinical-stage drug, to Revio Therapeutics for ...

Preservation of Skeletal Muscle Function Shown Over 3 Years Resulting in 52% Slowing of Disease----Data Presented at the 2025 Muscular ...

Roche to present latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association 2025 conference: Basel Tuesday, March 18, 2025, 11:00 Hrs [IST] ...

Having found that in biomedical research, the Bird Rock resident and scientist at La Jolla’s Sanford Burnham Prebys has ...

From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 ...

The Minnesota Department of Health tests for over 60 different disorders during a newborn screening, and now, two more ...

The impact of Illinois Gov. JB Pritzker’s plan to eliminate a health insurance program for noncitizen immigrants ages 42 to ...

The competition between U.S. and Chinese biotech companies is particularly fierce in one field: CRISPR gene editing. Here are ...

A man with a dentist phobia so severe he allowed most of his teeth to “crumble away” has now sought treatment abroad as he ...

BMO Capital analyst Kostas Biliouris initiated coverage of Dyne Therapeutics (DYN) with an Outperform rating and $50 price target The firm ...

Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

Don’t fall for the distraction of tariffs. To reduce fentanyl deaths, we need to get opioid users into treatment and reduce ...